171 related articles for article (PubMed ID: 1676210)
1. The hairless mouse as a model for study of local and systemic atrophogenic effects following topical application of corticosteroids.
van den Hoven WE; van den Berg TP; Korstanje C
Acta Derm Venereol; 1991; 71(1):29-31. PubMed ID: 1676210
[TBL] [Abstract][Full Text] [Related]
2. Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier impairment.
Ahn SK; Bak HN; Park BD; Kim YH; Youm JK; Choi EH; Hong SP; Lee SH
J Dermatol; 2006 Feb; 33(2):80-90. PubMed ID: 16556273
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy.
Schoepe S; Schäcke H; Bernd A; Zöller N; Asadullah K
Skin Pharmacol Physiol; 2010; 23(3):139-51. PubMed ID: 20051715
[TBL] [Abstract][Full Text] [Related]
4. The effects of topical and systemic glucocorticosteroids on DNA synthesis in different tissues of the hairless mouse.
Marshall RC; Burrows M; Brookes LG; du Vivier A
Br J Dermatol; 1981 Nov; 105(5):517-20. PubMed ID: 7295568
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model.
Zöller NN; Kippenberger S; Thaçi D; Mewes K; Spiegel M; Sättler A; Schultz M; Bereiter-Hahn J; Kaufmann R; Bernd A
Toxicol In Vitro; 2008 Apr; 22(3):747-59. PubMed ID: 18249522
[TBL] [Abstract][Full Text] [Related]
6. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
Serup J; Holm P
Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
[TBL] [Abstract][Full Text] [Related]
7. Comparative toxicity study of hydrocortisone 17-butyrate 21-propionate (HBP) ointment and other topical corticosteroids in rats.
Kimura M; Tarumoto Y; Nakane S; Otomo S
Drugs Exp Clin Res; 1986; 12(8):643-52. PubMed ID: 3757761
[TBL] [Abstract][Full Text] [Related]
8. The hairless mouse model for assaying the atrophogenicity of topical corticosteroids.
Woodbury R; Kligman AM
Acta Derm Venereol; 1992 Nov; 72(6):403-6. PubMed ID: 1362829
[TBL] [Abstract][Full Text] [Related]
9. Assessment of atrophogenicity of popularly prescribed topical corticosteroids.
Dykes PJ; Marks R; Blakemore CB
Br J Clin Pract; 1978 Dec; 32(12):345-8. PubMed ID: 737113
[No Abstract] [Full Text] [Related]
10. Methods for the assessment of skin atrophogenicity of topical corticosteroids.
Marks R
Dermatologica; 1976; 152 Suppl 1():117-26. PubMed ID: 133834
[TBL] [Abstract][Full Text] [Related]
11. Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers.
Kecskés A; Jahn P; Wendt H; Kleine-Kuhlmann R; Lange L
Arzneimittelforschung; 1993 Feb; 43(2):144-7. PubMed ID: 8457237
[TBL] [Abstract][Full Text] [Related]
12. A transgenic mouse model provides a novel biological assay of topical glucocorticosteroid potency.
Katchman SD; Del Monaco M; Wu M; Brown D; Hsu-Wong S; Uitto J
Arch Dermatol; 1995 Nov; 131(11):1274-8. PubMed ID: 7503571
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
Cossmann M; Welzel J
Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
[TBL] [Abstract][Full Text] [Related]
14. [Dermal and systemic side effects of fluocortin butylester. Comparative skin tearing experiments with active principles from commercial preparations].
Kapp JF; Gliwitzki B; Josefiuk P; Weishaupt W
Arzneimittelforschung; 1977; 27(11a):2206-13. PubMed ID: 580030
[TBL] [Abstract][Full Text] [Related]
15. Photoprotective effect of topical anti-inflammatory agents against ultraviolet radiation-induced chronic skin damage in the hairless mouse.
Bissett DL; Chatterjee R; Hannon DP
Photodermatol Photoimmunol Photomed; 1990 Aug; 7(4):153-8. PubMed ID: 2076370
[TBL] [Abstract][Full Text] [Related]
16. Objective evaluation of the efficacy of daily topical applications of cosmetics bases using the hairless mouse model of atopic dermatitis.
Matsumoto K; Mizukoshi K; Oyobikawa M; Ohshima H; Sakai Y; Tagami H
Skin Res Technol; 2005 Aug; 11(3):209-17. PubMed ID: 15998334
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory adrenal steroids that neither inhibit skin collagen synthesis nor cause dermal atrophy.
DiPetrillo T; Lee H; Cutroneo KR
Arch Dermatol; 1984 Jul; 120(7):878-83. PubMed ID: 6547287
[TBL] [Abstract][Full Text] [Related]
18. [Development and regression of dermal corticosteroid atrophy. 1. Change in the skinfold thickness].
Lubach D; Hinz E
Derm Beruf Umwelt; 1986; 34(5):146-9. PubMed ID: 2947794
[TBL] [Abstract][Full Text] [Related]
19. The effect of clobetasone butyrate and other topical steroids on skin thickness of the domestic pig.
Winter GD; Wilson L
Br J Dermatol; 1976 May; 94(5):545-50. PubMed ID: 1268065
[TBL] [Abstract][Full Text] [Related]
20. Shortened treatment duration of glucocorticoid-induced skin atrophy in rats.
Schoepe S; Vonk R; Schäcke H; Zollner TM; Asadullah K; Röse L
Exp Dermatol; 2011 Oct; 20(10):853-5. PubMed ID: 21824195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
